RASSF1A Suppresses Melanoma Development by Modulating Apoptosis and Cell‐cycle Progression
Mei Yi,Jianbo Yang,Xiang Chen,Ji Li,Xiayu Li,Li Wang,Yixin Tan,Wei Xiong,Ming Zhou,James B. Mccarthy,Guiyuan Li,Bo Xiang,Hongfu Xie
DOI: https://doi.org/10.1002/jcp.22568
2010-01-01
Journal of Cellular Physiology
Abstract:The tumor suppressor candidate gene Ras association domain family 1, isoform A (RASSF1A) encodes a microtubule‐associated protein that is implicated in the regulation of cell proliferation, migration, and apoptosis. Several studies indicate that down‐regulation of RASSF1A resulting from promoter hypermethylation is a frequent epigenetic abnormality in malignant melanoma. In this study, we report that compared with melanocytes in normal skins or benign skin lesions, RASSF1A is down‐regulated in melanoma tissues as well as cell lines, and its expression negatively correlates with lymph node metastasis. Following ectopic expression in RASSF1A‐deficient melanoma A375 cell line, RASSF1A reduces cell viability, suppresses cell‐cycle progression but enhances apoptotic cell death. In vivo, RASSF1A expression inhibits the tumorigenic potential of A375 cells in nude mice, which also correlates with decreased cell proliferation and increased apoptosis. On the molecular level, ectopic RASSF1A expression leads to differential expression of 209 genes, including 26 down‐regulated and 183 up‐regulated ones. Among different signaling pathways, activation of the apoptosis signal‐regulating kinase 1 (ASK1)/p38 MAP kinase signaling is essential for RASSF1A‐induced mitochondrial apoptosis, and the inhibition of the Akt/p70S6 kinase/eIF4E signaling is also important for RASSF1A‐mediated apoptosis and cell‐cycle arrest. This is the first study exploring the biological functions and the underlying mechanisms of RASSF1A during melanoma development. It also identifies potential targets for further diagnosis and clinical therapy. J. Cell. Physiol. 226: 2360–2369, 2011. © 2010 Wiley‐Liss, Inc.